Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;8(2):138-142.
doi: 10.1136/flgastro-2016-100763. Epub 2017 Feb 10.

Endoscopic management of Barrett's and early oesophageal neoplasia

G Lipman  1   2 , R J Haidry  1   2
Affiliations
Review

Endoscopic management of Barrett's and early oesophageal neoplasia

G Lipman et al. Frontline Gastroenterol. 2017 Apr.

Abstract

Barrett's oesophagus (BO) is the only known precursor to oesophageal adenocarcinoma (OAC). Dysplasia and intramucosal cancer arising in BO can safely be treated with endoscopic eradication therapy (EET) due to the low risk of subsequent lymph node metastasis. Treatment at an early stage is paramount due to the ongoing poor prognosis and outcomes of patients with advanced OAC. The mainstay of treatment is endoscopic resection of visible lesions for accurate staging followed by ablation therapy to all remaining columnar-lined epithelium, most commonly with radiofrequency ablation. Successful eradication of dysplasia can be achieved in >95% of patients with this EET combined approach.

Keywords: BARRETT'S CARCINOMA; BARRETT'S OESOPHAGUS; ENDOSCOPIC PROCEDURES; OESOPHAGEAL CANCER.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
i-Scan magnification endoscopy to demonstrate the loss of whitening after application of 2% acetic acid in dysplastic Barrett's oesophagus.
Figure 2
Figure 2
Radiofrequency ablation of Barrett's oesophagus. Circumferential Barrett's oesophagus prior to ablation (top left), placement of the 360 balloon catheter (top right) and following ablation (bottom left). Focal devices are also available (bottom right) (with permission from Medtronic).
See this image and copyright information in PMC

References

    1. Cancer Research UK. Oesophageal cancer incidence statistics 2013. (cited 1 August 2016). http://www.cancerresearchuk.org/health-professional/cancer-statistics/st...
    1. Pennathur A, Gibson MK, Jobe BA, et al. . Oesophageal carcinoma. Lancet 2013;381:400–12. doi:10.1016/S0140-6736(12)60643-6 - DOI - PubMed
    1. Wani S, Falk G, Hall M, et al. . Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011;9:220–7; quiz e26 doi:10.1016/j.cgh.2010.11.008 - DOI - PubMed
    1. Bhat S, Coleman HG, Yousef F, et al. . Risk of malignant progression in Barrett's Esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011;103:1049–57. doi:10.1093/jnci/djr203 - DOI - PMC - PubMed
    1. Hvid-Jensen F, Pedersen L, Drewes AM, et al. . Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365:1375–83. doi:10.1056/NEJMoa1103042 - DOI - PubMed

LinkOut - more resources